Venture Capital News and Headlines
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Venture Capital Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
Venture CapitalNewsMindImmune Therapeutics Closes $10.2M Series A Extension; Brings Round Total to $30M
MindImmune Therapeutics Closes $10.2M Series A Extension; Brings Round Total to $30M
Venture Capital

MindImmune Therapeutics Closes $10.2M Series A Extension; Brings Round Total to $30M

•November 25, 2025
0
FinSMEs
FinSMEs•Nov 25, 2025

Companies Mentioned

Frontier Pitts

Frontier Pitts

RightHill Ventures

RightHill Ventures

Dolby Family Ventures

Dolby Family Ventures

Pfizer Ventures

Pfizer Ventures

Why It Matters

The infusion of $30 million positions MindImmune to advance its pipeline in a high‑growth, unmet‑need area of neurodegeneration, while attracting strategic investors like Pfizer signals industry confidence and could pave the way for future partnerships or acquisitions.

MindImmune Therapeutics Closes $10.2M Series A Extension; Brings Round Total to $30M

Read Original Article
0

Comments

Want to join the conversation?

Loading comments...